Genmab, GlaxoSmithKline deal

GSK received global exclusive rights to co-develop and commercialize GEN's ofatumumab ( HuMax-CD20). GSK will pay a DKK582 million ($102 million) license fee and will invest DKK2 billion ($357 million) in

Read the full 314 word article

How to gain access

Continue reading with a
two-week free trial.